SHIN-ETSU-CHEMICAL
Shin-Etsu Chemical Co., Ltd., (Head Office: Tokyo; President: Yasuhiko Saitoh) has developed a new series of products, the KCP Series, a new vulcanization type of one-component liquid silicone rubber.
One-component liquid silicone rubber cures at room temperature by reacting to the atmospheric humidity. After curing, because it has superior combined characteristics, including heat resistance, cold resistance, weather resistance and outstanding electrical properties, it is used as adhesive/sealing materials and coating materials in such products as component parts for electric vehicles (EV), semiconductors, and electric/electronics. Furthermore, because it cures at room temperature, it is not necessary to have a heating furnace and ultraviolet (UV) irradiation equipment. Accordingly, these new products will contribute to reducing environmental impact.
The KCP Series of products are a type that releases cyclopentanone*1 at the time of the curing reaction. This new product series will meet the expectations of our customers with its improved vulcanization characteristics, higher level of safety and excellent handleability compared to existing products.*2 The main characteristics of these new products are as follows:
1: The vulcanization speed is fast and also the adhesion develops quickly, and thus work efficiency improves. The tack-free time*3 of KCP-102 is 3 minutes, ½ of the time of the existing KE-4898-W*4 product.
2: The odor that is generated at the time of curing is lower, and has a higher level of safety.
3: Because the ignition temperature is high, at more than 70 ℃, the handling time and effort needed during the time of transport and storage can be reduced.
4: It exhibits good adhesion with various resins and also there are almost no corrosive effects on metals.*5
There are 3 products lined up in the KCP Series according to their viscosity index: KCP-100 (low viscosity), KCP-101 (mid-viscosity) and KCP-102 (paste type). All of them are tube-type, and one can work simply by pushing the contents out from the tube-type container. Going forward, Shin-Etsu Chemical will continue to strive to meet the requests of our customers and develop products that have various added functions as we work to expand the line-up of our products.
Shin-Etsu Chemical will continue to endeavor to enhance our ability to contribute to the solution of various social and customer issues by developing and supplying advanced functional silicone products through making full use of the technological power and knowhow that Shin-Etsu has nurtured up to now, as we work to further contribute to the realization of the sustainability of society.
Footnotes:
*1 Cyclopentanone is an organic compound represented by the chemical formula (CH2 )4 CO. It is one of the cyclic ketones and is a volatile colorless liquid.
*2 Existing products include types of acetic acid, oxime, alcohol and acetone, and each have their own characteristics.
*3 It is the time that it takes until when one touches the surface, it will not stick to one’s finger.
*4 Curing Condition: 23℃/50%Relative Humidity
*5 Metal substrates should be tested prior to use with this product to insure performance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329006080/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
